In February 2026, Harmony Biosciences announced a significant milestone for families affected by narcolepsy. The U.S. Food and Drug Administration approved a supplemental new drug application for Wakix, also known by its generic name pitolisant, for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy.
This decision expands the therapeutic options available to children living with this rare and often misunderstood neurological sleep disorder. Wakix now becomes the first and only FDA-approved non-scheduled treatment for both pediatric and adult patients with narcolepsy with or without cataplexy.
In this in-depth blog, we explore what this approval means, how Wakix works, important safety information, and what families and clinicians should know moving forward.
Narcolepsy is a chronic neurological disorder that disrupts the brain’s ability to regulate sleep and wake cycles. It affects approximately 170,000 Americans and often begins in adolescence or young adulthood, although symptoms can appear earlier.
The two cardinal symptoms of narcolepsy are:
Excessive daytime sleepiness is present in all people living with narcolepsy. Individuals may struggle to stay awake during school, work, or conversations. Cataplexy can range from mild facial drooping to complete loss of muscle tone while remaining conscious.
Many cases of narcolepsy are linked to the loss of hypocretin, also called orexin, a neuropeptide that helps maintain stable wakefulness. Because the symptoms overlap with other conditions, diagnosis can take years, which adds to the burden on patients and families.
Wakix, or pitolisant, is a first in class medication and a selective histamine 3 receptor antagonist and inverse agonist. Unlike traditional stimulant medications used in narcolepsy, Wakix works by targeting the histamine system in the brain.
By blocking H3 receptors, Wakix increases the synthesis and release of histamine. Histamine is a wake-promoting neurotransmitter that plays a key role in maintaining alertness. While the exact mechanism of action is not fully understood, its therapeutic benefit is believed to be mediated through this increased histamine activity.
Wakix was originally approved by the FDA in 2019 for excessive daytime sleepiness in adults with narcolepsy. Approval was expanded in 2020 to include cataplexy in adults. In 2024, the FDA approved Wakix for excessive daytime sleepiness in pediatric patients aged 6 years and older. The 2026 approval now adds cataplexy treatment for pediatric patients, completing the spectrum of approved indications for children and adults.
The new approval means that clinicians can prescribe Wakix to treat both excessive daytime sleepiness and cataplexy in pediatric patients 6 years of age and older.
Several aspects make this especially important:
Wakix is not classified as a controlled substance. Many traditional treatments for narcolepsy, particularly stimulant medications, fall under controlled substance regulations. This can create additional prescribing restrictions and concerns for families.
Having a non-scheduled treatment option provides clinicians with greater flexibility and may reduce administrative burdens for caregivers.
Children with narcolepsy often experience both excessive daytime sleepiness and cataplexy. The ability to address both symptoms with one FDA approved medication simplifies treatment strategies.
Because Wakix is now approved for both pediatric and adult populations, it allows for continuity of care as patients transition from childhood into adulthood.
Wakix is indicated for the treatment of:
The medication is available by prescription only.
As with any prescription medication, understanding safety considerations is essential. Below is a summary of key safety information associated with Wakix.
Wakix is contraindicated in patients with:
Anaphylaxis has been reported in association with pitolisant.
Wakix has been shown to prolong the QT interval. It should be avoided in:
The risk of QT prolongation may be higher in patients with hepatic or renal impairment. Monitoring may be required in these populations.
In placebo-controlled trials involving adults with narcolepsy with or without cataplexy, the most common adverse reactions reported at rates of 5 percent or greater and at least twice placebo included:
Other reported reactions included headache, upper respiratory tract infection, musculoskeletal pain, increased heart rate, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, dry mouth, rash, and cataplexy.
In pediatric clinical trials involving patients 6 years and older, the most common adverse reactions were:
The overall adverse reaction profile in children was similar to that observed in adults.
Wakix interacts with certain medications and metabolic pathways. Important considerations include:
Clinicians should review a patient’s full medication list before initiating therapy.
There is a pregnancy exposure registry that monitors outcomes in women exposed to Wakix during pregnancy. Patients who become pregnant while taking Wakix are encouraged to enroll in the registry.
Wakix is extensively metabolized by the liver. It is contraindicated in patients with severe hepatic impairment. Dose adjustments are required in moderate hepatic impairment and in patients with reduced kidney function. Wakix is not recommended in patients with end-stage renal disease.
Patients who are CYP2D6 poor metabolizers may have higher pitolisant concentrations and increased risk of adverse events. Lower maximum recommended dosages apply in this population.
Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases. Established in 2017 and headquartered in Plymouth Meeting, Pennsylvania, the company has centered its efforts on advancing pitolisant for narcolepsy and exploring additional potential indications.
With this pediatric cataplexy approval, Harmony continues to expand the clinical footprint of Wakix and pursue additional regulatory exclusivity opportunities. The company has indicated ongoing development plans, including next-generation formulations.
The expansion of Wakix into pediatric cataplexy treatment reflects a broader trend in sleep medicine. Historically, many therapies were studied primarily in adult populations. Pediatric patients often relied on off-label use or adapted adult regimens.
An FDA approval specifically for pediatric cataplexy offers several advantages:
As awareness of narcolepsy grows, earlier diagnosis and treatment may become more achievable.
The approval of Wakix for cataplexy in pediatric patients marks an important development in narcolepsy care. For families navigating the challenges of excessive daytime sleepiness and sudden muscle weakness episodes, having an additional FDA-approved treatment option can provide reassurance.
However, treatment decisions must always be individualized. Factors such as symptom severity, comorbid conditions, medication tolerability, and lifestyle considerations should all be taken into account.
Patients and caregivers should work closely with qualified healthcare professionals to determine whether Wakix is appropriate for their specific situation.
Harmony Biosciences Holdings, Inc. Press Release. February 17, 2026.
This article is intended for informational and educational purposes only and is optimized for general search visibility. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare provider regarding any medical condition or treatment decisions. Medication safety information is summarized and not comprehensive. Refer to the official prescribing information and speak with a healthcare professional for complete details.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.